GRI Bio (GRI) vs Onconetix (ONCO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
GRI Bio is the larger company by market cap ($3.8 million vs $3.3 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GRI | ONCO |
|---|---|---|
| Share price | $1.74 | $0.6358 |
| Market cap | $3.80M | $3.33M |
| 1-day change | +3.57% | -2.83% |
| P/E ratio (TTM) | — | 0.00 |
| EPS (TTM) | $-14.71 | $310.39 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $64.12 | $207.00 |
| 52-week low | $1.36 | $0.58 |
| Distance from 52-week high | -97.29% | -99.69% |
| Analyst consensus | none | — |
| Avg. price target upside | +963.22% | — |
| Average volume | 328.24K | 2.96M |
| Shares outstanding | 2.19M | 5.24M |
| Employees | 3 | 2 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About GRI Bio
GRI stock →GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis.
Health Care · Biotechnology: Pharmaceutical Preparations · 3 employees
About Onconetix
ONCO stock →Onconetix, Inc., a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology in the United States, the European Union, and Non-European Union. The company offers Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 2 employees
GRI vs ONCO FAQ
Which is bigger, GRI Bio or Onconetix?
GRI Bio (GRI) is larger, with a market capitalization of $3.80M compared with $3.33M for Onconetix (ONCO).
Are GRI Bio and Onconetix in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.